Plain-English translation of NCT00722228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a cancer vaccine approach where doctors grow your own tumor cells in the laboratory, modify them to wake up your immune system, and then inject them back into you. The goal is to help your body's natural defenses recognize and fight the cancer that has spread. Researchers believe this treatment may help people with melanoma, breast, ovarian, colorectal, gastric, lung, or kidney cancer live longer.
Standard chemotherapy doesn't always work for cancer that has spread throughout the body, and many patients need new options. This trial exists to see whether training your own immune system to attack cancer cells could offer better outcomes than current treatments alone.
You likely qualify if…
You likely don't qualify if…
You would receive five injections of the modified cancer vaccine under your skin, spaced three weeks apart. The vaccine is made from your own tumor cells that have been processed in a laboratory to make them stronger at triggering your immune system. Over the course of the study, you'll have regular check-ups to see how your body is responding and whether your cancer is improving.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Israel
Phase
Safety & dosing / Early efficacy
Sponsor
Hadassah Medical Organization
Enrollment target
~50 participants
Started
July 2008
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hani Steinberg, R.N. B.A.
Hadassah Medical Organization
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.